Pulmonary Edema Market Industry Overview, Size, Share, Growth Trends, Research Insights and Forecast (2025–2032)

Pulmonary Edema Market Overview

Pulmonary edema occurs when additional fluid accumulates in the lungs. The accumulation of fluid causes difficulty in breathing and increases pressure in the lungs, causing liquid leakage. Other factors responsible for fluid accumulation include infection, toxic risk and high height. Fulflene edema also increases the prevalence of heart diseases. According to the WHO, heart disease causes 16.8 million deaths annually. During COVID-19, the cases of pulmonary edema increased, especially in severe infections. SARS-CoV-2 causes fluid buildup. Recent developments in new drugs for pulmonary edema include sotolamide and cellubritil. Solnatide is a synthetic peptide. Solnatide helps to withdraw fluid from the sodium channel in the lungs. This syndrome is associated with COVID-19-related heart failure.

 

Sacubitril is used in combination with Valsartan, which prevents neprilysin enzymes. The NePlisin enzyme degraded the natural peptides. Sacubitril helps reduce the amount of blood and pressure, further reducing fluid accumulation in the lungs.

 

This innovation offers the option of existing drugs for managing pulmonary edema. Many major players include pulmonary edema treatment markets, especially in combination with Sacubitril and Valsartan. Lupine Limited received American approval for generic cobtril and Valstartan Tablet in January 2025. In addition, in September 2024, Biocon also received FDA approval for pulmonary edema drugs. Glenmark Pharmaceuticals in India began a 'Seku V' combination in January 2024 at an affordable rate.

 

 

To get more Insights: Request Free Sample Report

 

Pulmonary Edema Market Dynamics

Rising Prevalence of Cardiovascular Disease (CVDs) to Drive Pulmonary Edema Market

Heart disease is an important cause of mortality. According to the World Health Organization (WHO), heart disease is responsible for about 16.8 million deaths annually. These diseases include heart and blood vessel dissolution, coronary artery disease and many disorders of hypertension, leading to pulmonary edema. The World Health Organization (WHO) has emphasized that CVD deaths are caused by heart attacks and strokes, affecting one-third of a population of 70 years of age. The increasing proliferation of CVD has increased the demand for effective management strategies for complications such as pulmonary edema.

 

Increasing Incidence of Road Accidents Causing Chest Injuries to Drive the Pulmonary Edema Market

Contingency injuries are a major global health issue, causing about 1.19 million deaths each year. In particular, these injuries are 5–29 years old and are the major causes of death for young adults. Chest damage caused by such accidents can lead to acute respiratory complications, including pulmonary edema. The adequate economic burden of road traffic, with a cost of about 3% of its GDP, underlines the important need for advanced medical intervention to manage and reduce these health effects.

 

Aging Global Population and Increased Susceptibility to Grow Pulmonary Edema Market

Global demographic changes towards an older population have intensively implications for public health. Older individuals have a greater risk of developing heart and kidney conditions, which are primary risk factors for pulmonary edema. The WHO reports that in non-communicable diseases, including CVD, is low, and 75% of all deaths globally with middle-aged countries. As the elderly population increases, there is a need to demand an increase in incidence of age-related diseases, including pulmonary edema, an increase in health services and demand for driving in the pulmonary edema market.

 

Pulmonary Edema Market Segment Analysis

Based on Disease Type Pulmonary Edema Market is segmented into cardiogenic pulmonary edema and non-cardiogenic pulmonary edema. Cardiogenic pulmonary edema type leads the market. It is mainly associated with heart failure. According to Cleveland Clinic reports, about 6 million American adults have heart failure, and 80% of them experience pulmonary edema. Reports suggest that only 50% survive after one year of diagnosis, and 85% die within six years. Common causes include coronary artery disease, cardiomyopathy, and heart valve disorders. Treatment includes surgery, such as a diuretic, vasodilator, or bypass grafting and valve repair. Non-cardiogenic pulmonary edema is caused by lung injury, not due to heart problems. Conditions such as ARDS, infection, toxic breathing, or trauma can cause this. The Mayo Clinic states that high altitude risks can lead to high altitude pulmonary edema (HAPE), which may be life-threatening. Treatment focuses on oxygen therapy and, in severe cases, mechanical ventilation.

 

 

Based on Diagnosis Type Bottom of Forme, the Pulmonary Edema Market is segmented into imaging techniques and laboratory tests. Imaging techniques lead the pulmonary edema market. Chest X-ray is the most common imaging method for detecting fluid in the lungs, but the study suggests that CT scans provide more accurate results. Research also indicates that lung ultrasound, combined with deep learning techniques, can automatically assess the severity of pulmonary edema. Blood tests help evaluate oxygen levels and detect underlying conditions such as heart failure or infection. In cases of hantavirus pulmonary syndrome, laboratory results often show hemocytopenia, neutrophilic leukocytosis, and thrombocytopenia. A combination of imaging and laboratory tests allows initial diagnosis and better treatment results.

 

Based on Treatment Type, the Pulmonary Edema Market is segmented into oxygen therapy, medications, and surgical interventions. The pulmonary edema, which is characterized by fluid accumulation in the lungs, requires quick treatment to improve the results of the patient. Oxygen therapy is often the first line of treatment, which provides oxygen through face mask or nasal penetration to reduce symptoms. Medications play an important role; The diuretic helps to remove additional fluids by increasing the production of urine, while other drugs can increase heart function to prevent further liquid buildups. In severe cases, surgical intervention such as coronary artery bypass grafting or valve repair may require to address the underlying heart issues contributing to the pulmonary edema. According to WHO, more than 1 million patients are recruited annually with pulmonary edema for heart -related reasons. Early and proper treatment is necessary for people to reduce mortality and improve the quality of life.

 

 

Based on End User, the pulmonary edema market is segmented into hospitals and clinics, academic institutes, and ambulatory surgical centers. Hospitals and clinics are primary centers for the diagnosis and treatment of pulmonary edema. In the United States, acute cardiogenic pulmonary edema enters 1 million hospitals annually, causing about 6.5 million hospitalizations every year. In England and Wales, acute heart failure, a common cause of pulmonary edema, more than 67,000 hospital admissions per year. Acute pulmonary edema varies in the hospital mortality for patients; some studies have a reporting rate of 12% higher, and one-year mortality reaches 40%. According to the National Institute of Health (NIH), it conducted extensive research in pulmonary edema and acute lung injuries, supporting over 11,000 grants worth more than $ 600 million annually by 1970.

 

Pulmonary Edema Market Regional Analysis

North America

It shows dominance in the pulmonary edema market in 2024. North America is a well-developed healthcare sector, which has high per capita healthcare expenses. Global pulmonary edema dominates the market due to the presence of prominent players such as LifeSycense Corporation.In the United States, acute cardiogenic pulmonary edema accounts for around 1 million hospital admissions annually, accounting for about 6.5 million hospital admissions every year. In England and Wales, acute heart failure, a common cause of pulmonary edema, more than 67,000 hospital admissions per year. Acute pulmonary edema varies in the hospital mortality for patients; some studies have a reporting rate of 12% higher, and one-year mortality reaches 40%. These data outline the significant burden of pulmonary edema on the healthcare system and highlight the need for effective management and treatment strategies to suit regional health capabilities.

 

Pulmonary Edema Market Competitive Landscape

Many major players in the pulmonary edema treatment market facilitate progress in patient care. Among notable companies, Fizer Ink, Argon Medical, Edwards Life Sciences Corporation, BD (Bercin, Dickinson & Company), Medtronic, Koninklijke Philips NV, Siemens Healthier AG, Lupine Pahmasite Ink, Vitalttech Corporation, and Novartis AG. In recent developments, the Merc prevented its late-phase study of the pulmonary arterial hypertension drug due to strong efficacy data. This decision underlines the significant effect of the drug when the PAH -related mortality is reduced. Conversely, Kerose Therapeutics faced challenges when unexpected side effects suspended high doses in their lead drug tests for pulmonary artery hypertension.

 

Industry Consolidation:

Company	Date	Type of Activity	Description
ResMed and Propeller Health	April 2023	Acquisition	ResMed acquired Propeller Health, enhancing its portfolio in remote patient monitoring and data-driven care management for respiratory diseases, including pulmonary edema.
AstraZeneca and BioNTech	March 2023	Collaboration	AstraZeneca collaborated with BioNTech to develop novel immuno-oncology therapies, targeting conditions such as pulmonary edema associated with lung cancer.
Novartis	November 2023	FDA Approval	Novartis received FDA approval for Entresto (sacubitril/valsartan) for treating heart failure with preserved ejection fraction (HFpEF), a condition that can lead to pulmonary edema.
Verve Therapeutics	September 2023	Clinical Trial Initiation	Verve Therapeutics dosed the first patient in a Phase 1b clinical trial for VERVE-101, a potential gene therapy for pulmonary edema associated with pulmonary arterial hypertension.

 

Pulmonary Edema Market Scope
Market Size in 2024	USD 6.6 Bn.
Market Size in 2032	USD 12.04 Bn.
CAGR (2025-2032)	9.8%
Historic Data	2019-2024
Base Year	2024
Forecast Period	2025-2032
Segments	By Disease Type              Cardiogenic Pulmonary Edema Non-Cardiogenic Pulmonary Edema
	By Diagnosis Imaging Techniques Laboratory Tests
	By Treatment Oxygen Therapy Medications               Surgical Interventions
	By End-User Hospitals and Clinics Academic Institutes Ambulatory Surgical Centers
Regional Scope	North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Russia, and the Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, Taiwan, Philippines, Indonesia, Vietnam, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America

 

Key Players in the Pulmonary Edema Market

North America

1. Pfizer Inc. (USA)
2. ARGON MEDICAL (USA)
3. Edwards Lifesciences Corporation (USA)
4. BD (Becton, Dickinson and Company) (USA)
5. Abbott Laboratories (USA)
6. Johnson & Johnson (USA)
7. Merck & Co. (USA)
8. GE Healthcare (USA)
9. ResMed (USA)
10. United Therapeutics Corporation (USA)
11. Boehringer Laboratories (USA)
12. Medtronic ( USA )
13. AstraZeneca (UK)

 

Europe

14. Bayer AG (Germany)
15. Boehringer Ingelheim (Germany)
16. Siemens Healthcare GmbH (Germany)
17. Fresenius Medical Care (Germany)
18. Novartis AG (Switzerland)
19. Roche Holding AG (Switzerland)
20. Actelion Pharmaceuticals Ltd. (Switzerland)
21. Sanofi S.A. (France)
22. Chiesi Farmaceutici (Italy)
23. Koninklijke Philips N.V. (Netherlands)
24. GlaxoSmithKline plc (UK)

 

Asia Pacific

25. Lupin Pharmaceuticals (India)
26. Hitachi Medical Corporation (Japan)
27. Canon Medical Systems Corporation (Japan)
28. Vitaltec Corporation (Taiwan)